Reißig Timm M, Siveke Jens T
Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Deutschland.
Brückeninstitut für Experimentelle Tumortherapie (BIT), Westdeutsches Tumorzentrum, Universitätsklinikum Essen, Essen, Deutschland.
Chirurg. 2021 Sep;92(9):803-808. doi: 10.1007/s00104-021-01454-1. Epub 2021 Jul 6.
Ampullary carcinoma is a rare malignant neoplasm and arises in the region of Vater's ampulla. The differentiation from pancreatic and distal cholangiocarcinoma can be difficult. The prognosis is more favorable than for pancreatic ductal adenocarcinoma but recurrences are frequent. An exact diagnostic clarification and differentiation from pancreatic carcinoma is therefore essential. Although the resection of periampullary carcinoma is established, prospectively controlled studies on the role of multimodal treatment are rare. Adjuvant chemotherapy is oriented to the protocols for pancreatic carcinoma and could be of benefit in lymph node metastases, advanced T stage and low differentiation of tumors. Intestinal and pancreatobiliary subtypes can be differentiated histologically, which is relevant for systemic treatment strategies. Patients with pancreatobiliary differentiated tumors in particular could benefit from gemcitabine-based treatment but insufficient evidence exists for chemoradiotherapy. The role of neoadjuvant and perioperative treatment strategies is currently unclear. Molecular characterization can help to identify familial risk constellations and targeted treatment strategies for this rare tumor entity.
壶腹癌是一种罕见的恶性肿瘤,起源于 Vater 壶腹区域。与胰腺癌和远端胆管癌的鉴别可能较为困难。其预后比胰腺导管腺癌更有利,但复发频繁。因此,准确的诊断及与胰腺癌的鉴别至关重要。尽管壶腹周围癌的切除术已确立,但关于多模式治疗作用的前瞻性对照研究却很少。辅助化疗遵循胰腺癌的方案,可能对淋巴结转移、晚期 T 分期和肿瘤低分化有益。肠道型和胰胆管型可通过组织学进行区分,这与全身治疗策略相关。特别是胰胆管分化肿瘤的患者可能从基于吉西他滨的治疗中获益,但放化疗的证据不足。新辅助和围手术期治疗策略的作用目前尚不清楚。分子特征分析有助于识别这种罕见肿瘤实体的家族性风险组合和靶向治疗策略。